In 1992, an extremely visible lobbying advertising campaign by grassroots advocacy agencies increased consciousness among policymakers of the necessity to expand funding for breasts cancer research. These customer groups emphasized the need to fund research in ways that were not the same as those utilized by traditional medical analysis organizations like the National Institutes of Health. In response, america Congress allocated specific funds for breast cancer analysis in the DOD appropriations spending budget.The upsurge in revenue for the next quarter and first half a year of 2010 was due to growth from product sales of the INTERCEPT Blood System. Product income for the INTERCEPT Bloodstream System was $5.7 million during the second quarter of 2010, representing a rise of $1.8 million, or 47 percent, from the second quarter of 2009. Despite average foreign exchange rate erosion of 8 percent between the U.S. Dollar and the Euro, product revenue grew by 4 percent from the first one fourth of 2010. Product revenue for the first half a year of 2010 was $11.2 million, up from $7.0 million during the first six months of 2009. Government grant revenue recognized through the second one fourth of 2010 was $0.2 million, compared to $0.3 million recognized through the second quarter of 2009.